Bausch + Lomb (BLCO) BL1332 Misses Phase 2 Primary Endpoint
Bausch + Lomb's (BLCO) Phase 2 study for BL1332 missed its primary endpoint, showing no statistically significant improvement over the vehicle. The LS mean differences were -11.5 and -9.0, favoring BL1332 but not reaching significance. A 0.30% dose showed nominal significance at six hours for a secondary endpoint, with adverse event rates reported but no serious events.
How this was made

The 30-second read
Why it matters
A primary endpoint miss typically reduces the probability of advancement or label-enabling evidence, increasing uncertainty around timelines and future capital needs.
Market read
Traders can reassess BL1332’s development odds and the near-term risk premium for BLCO based on the primary endpoint miss.
What to watch
The article does not provide safety severity details beyond rates, nor does it clarify trial design, sample size, or whether the miss was close to significance, which could moderate the market reaction.
Background
The piece summarizes a Phase 2 readout for Bausch + Lomb’s BL1332, focusing on endpoint significance versus vehicle.
Ticker impact
Bausch + Lomb’s BL1332 Phase 2 trial missed the primary endpoint, with no statistically significant improvement versus vehicle.
Likely downside bias as traders price reduced probability of future development success and potential partner or financing risk.
The article explicitly states the primary endpoint was not statistically significant versus vehicle, which is a direct negative clinical readout.
Market effects
Adds to the evidence of higher clinical-development risk for ophthalmology/biopharma programs, potentially weighing on peer sentiment.
Limited, mostly affects US-listed biotech sentiment rather than broad regional flows.
Low, as the catalyst is company-specific clinical trial efficacy.
Counterpoint
Secondary and exploratory signals (including complete relief at six hours) could keep optionality alive for further dose refinement or subgroup analyses.
Key entities
- companyBausch + Lomb
US-listed ophthalmic drug developer; subject of the Phase 2 BL1332 efficacy readout.
- drug_programBL1332
Bausch + Lomb Phase 2 candidate evaluated against vehicle with primary and secondary endpoints.

